国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为上 海健麾信息技术股份有限公司（以下简称"公司"或"健麾信息"）首次公开 发行股票并上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》等相关法律、法规和规范性文件的要求，就健麾信息 使用部分闲置募集资金临时补充流动资金事项进行了审慎尽职调查，核查情况 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于核准 上海健麾信息技术股份有限公司首次公开发行股票的批复》（证监许可 [2020]3211号），公司于2020年12月首次公开发行人民币普通股（A股）34,000,000 股。公司每股发行价格为人民币14.20元，本次募集资金总额为人民币 482,800,000.00元，扣除各项发行费用（不含增值税）人民币47,588,127.72元， 实际募集资金净额为人民币435,211,872.28元。上述募集资金到位情况已经立信 会计师事务所（特殊普通合伙）于2020年12月 ...

第三届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海健麾信息技术股份有限公司（以下简称"公司"）第三届监事会第四次 会议于 2024 年 10 月 29 日下午以现场结合通讯方式召开，会议通知及相关材料 已于 2024 年 10 月 22 日通过电子邮件方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人，全体监事均亲自出席了本次会议。本次会议由公司监 事会主席刘羽洋先生主持。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》等有关规定。 二、监事会会议审议情况 经与会监事认真审议，会议形成了以下决议： 1、 审议通过《关于<2024 年第三季度报告>的议案》 证券代码：605186 证券简称： 健麾信息 公告编号：2024-038 上海健麾信息技术股份有限公司 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2、审议通过《关于使用部分闲置募集资金临时补充流动资金的议案》 公司拟使用部分闲置募集资金不超过 9,000 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥49,716,421.41, a decrease of 22.75% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥2,507,112.05, down 86.25% year-on-year[2] - The net profit after deducting non-recurring gains and losses for Q3 2024 was -¥3,277,216.37, a decline of 153.48% compared to the same period last year[2] - The basic earnings per share for Q3 2024 was ¥0.02, representing a decrease of 84.62% year-on-year[3] - Total operating revenue for the first three quarters of 2024 was CNY 195,235,835.09, a decrease of 19.1% compared to CNY 241,228,692.12 in the same period of 2023[16] - Net profit for the first three quarters of 2024 was CNY 26,679,245.72, a decline of 64.1% compared to CNY 74,485,546.03 in 2023[17] - Earnings per share for the first three quarters of 2024 were CNY 0.24, down from CNY 0.54 in the same period of 2023[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,440,873,118.91, an increase of 9.42% from the end of the previous year[3] - The total equity attributable to shareholders at the end of the reporting period was ¥1,071,177,923.22, reflecting a slight increase of 1.75% from the previous year[3] - Total liabilities increased to CNY 290,080,453.09 in Q3 2024, compared to CNY 179,057,693.66 in Q3 2023, reflecting a growth of 62.2%[15] - Total equity as of Q3 2024 was CNY 1,150,792,665.82, an increase from CNY 1,137,713,420.10 in Q3 2023[15] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥64,112,098.52, indicating a significant cash outflow[3] - In the first three quarters of 2024, the cash inflow from operating activities totaled ¥188,589,844.46, a decrease of 14.8% compared to ¥221,343,371.29 in the same period of 2023[20] - The net cash outflow from operating activities was ¥64,112,098.52, slightly worse than the previous year's outflow of ¥60,962,902.96[20] - The cash inflow from financing activities increased significantly to ¥148,825,511.07 in 2024, compared to ¥50,590,000.00 in 2023, marking a growth of 194.5%[21] - The total cash and cash equivalents at the end of Q3 2024 stood at ¥166,745,736.34, down from ¥231,996,500.60 at the end of Q3 2023, reflecting a decrease of 28.1%[21] Operational Insights - The decline in net profit was attributed to external factors, including industry supply-demand adjustments and limited channel expansion[8] - The company reported a significant increase in accounts payable, reaching CNY 63,318,001.99 in Q3 2024, compared to CNY 59,664,012.67 in Q3 2023[15] - Deferred income tax liabilities rose to CNY 1,122,529.87 in Q3 2024, up from CNY 104,244.11 in Q3 2023, indicating a substantial increase in tax obligations[15] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[11] - There are no other significant reminders regarding the company's operational performance during the reporting period[12] Asset Composition - As of September 30, 2024, the company's current assets totaled approximately ¥818.86 million, an increase from ¥771.44 million at the end of 2023[13] - Accounts receivable increased to ¥503.99 million from ¥384.33 million year-over-year, indicating a growth of approximately 31.1%[13] - The company's non-current assets amounted to ¥622.02 million, up from ¥545.33 million, reflecting a growth of about 14.1%[13] - Cash and cash equivalents decreased to ¥169.36 million from ¥267.76 million, a decline of approximately 36.7%[12] - Inventory increased to ¥81.57 million from ¥65.16 million, representing a growth of about 25.2%[13] - The company reported a significant increase in long-term equity investments, rising to ¥116.18 million from ¥106.26 million, a growth of approximately 9.1%[13] Research and Development - Research and development expenses for the first three quarters of 2024 were CNY 18,663,790.52, slightly down from CNY 18,805,098.22 in 2023[16] Financial Expenses - Financial expenses for Q3 2024 were CNY 1,537,685.39, compared to a financial income of CNY 1,308,283.50 in Q3 2023[17]

证券代码：605186 证券简称： 健麾信息 公告编号：2024-037 上海健麾信息技术股份有限公司 上海健麾信息技术股份有限公司（以下简称"公司"）第三届董事会第四次 会议于 2024 年 10 月 29 日下午以现场结合通讯方式召开，会议通知及相关材料 已于 2024 年 10 月 22 日通过电子邮件方式送达各位董事。本次会议应出席董事 8 人，实际出席董事 8 人，全体董事均亲自出席了本次会议。本次会议由公司董 事长戴建伟先生主持，公司全体监事和高级管理人员列席。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》等有关规定。 二、董事会会议审议情况 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 经与会董事认真审议，会议形成了以下决议： 1、审议通过《关于<2024 年第三季度报告>的议案》 根据《中华人民共和国证券法》、《上海证券交易所股票上市规则》、《上海证 券交易所上市公司自律监管指南第 1 号-公告格式》等规定，公司对 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-036 上海健麾信息技术股份有限公司 关于使用部分闲置募集资金临时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海健麾信息技术股份有限公司（以下简称"公司"）拟使用部分闲置募集 资金9,000.00万元临时补充流动资金，使用期限自董事会审议通过之日起不超过 12个月。 单位：万元 | 序号 | 项目名称 | 总投资额 | 拟使用募集资金投入金额 | | --- | --- | --- | --- | | 1 | 健麾信息医药物流智能产业化项目 | 29,889.00 | 23,000.00 | | 2 | 市场营销与客户服务网络升级项目 | 6,254.00 | 1,000.00 | | 3 | 医药物流机器人实验室建设项目 | 4,518.50 | 1,000.00 | | 4 | 药房自动化升级研发项目 | 9,862.20 | 2,000.00 | | 5 | 自动化设备投放项目 | 13,462.00 | 10,00 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-039 一、计提资产减值准备情况概述 根据《企业会计准则》以及公司会计政策的相关规定，为真实、客观地 反映公司截至2024年9月30日的财务状况及经营成果，基于谨慎性原则，公 司对截至2024年9月30日存在减值迹象的相关资产计提减值准备。2024年前 三季度确认的各项信用减值损失合计为21,823,029.20元。主要如下： 单位：元 | 序号 | 项目 | 2024年前三季度计提减值损失金额 | | --- | --- | --- | | 1 | 信用减值损失 | 21,823,029.20 | | 其中： | 应收账款坏账损失 | 21,823,029.20 | | | 合计 | 21,823,029.20 | 二、计提依据 本公司对以摊余成本计量的金融资产以预期信用损失为基础进行减值会 计处理。 本公司考虑有关过去事项、当前状况以及对未来经济状况的预测等合理 且有依据的信息，以发生违约的风险为权重，计算合同应收的现金流量与预 期能收到的现金流量之间差额的现值的概率加权金额，确认预期信用损失。 上海健麾信息技术股份有限公司 关于2024年前 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-035 上海健麾信息技术股份有限公司关于使用部分 闲置募集资金临时补充流动资金归还的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海健麾信息技术股份有限公司（以下简称"公司"）于2023年10月27日召 开了第二届董事会第十八次会议、第二届监事会第十五次会议，审议通过了《关 于使用部分闲置募集资金临时补充流动资金的议案》，为提高募集资金使用效率， 降低公司财务成本，公司在确保不影响募集资金投资项目建设进度的前提下，拟使 用总额度不超过人民币1.20亿元的部分闲置募集资金临时补充流动资金，期限不 超过12个月，并且公司将根据募投项目的进展及需求情况及时归还资金至募集 资金专户。具体情况详见公司于2023年10月31日在上海证券交易所网站 （www.sse.com.cn）披露的《关于使用部分闲置募集资金临时补充流动资金的 公告》（公告编号：2023-025）。 截至本公告披露日，公司实际使用闲置募集资金临时补充流动资金9,206.38万 元，已将上述募集资金 ...

Group 1: Company Overview and Strategy - The company focuses on providing intelligent management solutions for the pharmaceutical industry, driven by technological innovation to meet market demands [1] - It aims to strengthen its research and development capabilities and actively seeks overseas collaboration opportunities to compensate for domestic demand shortages [1][2] Group 2: Financial Performance - In the first half of 2024, the company reported a revenue of 145.5194 million yuan, a decrease of 17.73% compared to the same period last year [2] - The net profit attributable to shareholders was 29.5444 million yuan, reflecting a decline of 47.06% year-on-year [2] Group 3: Technological Innovation and Market Adaptation - The company has a well-established R&D system with a team that has nearly 20 years of experience in the industry, demonstrating strong capabilities in technological innovation and product development [2] - In response to the slowdown in domestic market demand for automated pharmacy upgrades, the company is adjusting its strategy to expand into overseas markets with customized R&D efforts [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：605186 证券简称：健麾信息 公告编号：2024-034 上海健麾信息技术股份有限公司 关于召开 2024 年半年度业绩说明会的公告 https://roadshow.sseinfo.com/） 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 10 月 11 日 下午 14:00-15:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 09 月 27 日(星期五) 至 10 月 10 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 stock@g-healthy.com 进行提问。公司将在说明会上 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2024, representing a 15% increase compared to the same period last year[6]. - The company's operating revenue for the first half of 2024 was ¥145,519,413.68, a decrease of 17.73% compared to ¥176,872,071.25 in the same period last year[14]. - The net profit attributable to shareholders for the first half of 2024 was ¥29,544,390.93, down 47.06% from ¥55,812,371.66 year-on-year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,355,500.83, a decline of 58.04% compared to ¥53,278,951.34 in the previous year[14]. - The net cash flow from operating activities was -¥124,102,988.86, indicating a significant cash outflow compared to -¥71,395,692.74 in the same period last year[14]. - The basic earnings per share for the first half of 2024 were ¥0.22, down 46.34% from ¥0.41 in the same period last year[15]. - The diluted earnings per share were also ¥0.22, reflecting the same percentage decrease of 46.34% compared to the previous year[15]. - The weighted average return on equity decreased by 2.63 percentage points to 2.77% from 5.40% year-on-year[15]. - The company faced challenges due to a complex external economic environment and a decline in effective domestic demand, impacting overall performance in the first half of 2024[16]. Revenue Guidance and Projections - The company has provided a revenue guidance of RMB 220 million for the full year 2024, indicating an expected growth of 10%[6]. - The company reported a significant increase in revenue for the first half of 2024, achieving a total of $500 million, representing a 25% growth compared to the same period last year[63]. - User data showed a 15% increase in active users, reaching 2 million by the end of June 2024[64]. - The company provided guidance for the second half of 2024, projecting revenue growth of 20% year-over-year, aiming for $600 million[65]. - New product launches are expected to contribute an additional $100 million in revenue, with a focus on innovative technology solutions[66]. Market Expansion and Strategic Initiatives - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[6]. - The company is actively expanding its overseas market presence, having signed agreements with distributors in regions such as Hong Kong, Europe, and Southeast Asia, and has begun supplying products to Saudi Arabia and Russia[39]. - The company has established a joint venture in Riyadh, Saudi Arabia, with Ajlan & Bros Information Technology Company to promote its products in the Middle East and North Africa markets, leveraging successful past collaborations[39]. - The company has signed strategic cooperation agreements with major players in the pharmaceutical retail sector, including Meituan, to develop a "smart pharmacy" model that integrates technology and retail[40]. Product Development and Innovation - New product development includes the launch of a healthcare management system, which is projected to generate an additional RMB 30 million in revenue by the end of 2024[6]. - The company is currently developing new products, including hospital logistics robots and automated drug dispensing machines, to expand its service offerings[28]. - The company emphasizes the importance of new product research and development to maintain its competitive edge in the market[28]. - The company has developed a comprehensive R&D system and has a team with nearly 20 years of experience in intelligent drug management projects, enhancing its technical innovation and product development capabilities[32]. Financial Health and Investments - The total assets at the end of the reporting period were ¥1,360,400,054.78, reflecting a 3.31% increase from ¥1,316,771,113.76 at the end of the previous year[14]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,082,270,811.17, an increase of 2.81% from ¥1,052,726,420.24 at the end of the previous year[14]. - The company has invested RMB 5 million in R&D for new technologies aimed at improving service efficiency[6]. - The company has a total of ¥15,117,454.75 in overseas assets, accounting for 1.11% of total assets[46]. - The company invested a total of ¥44,599,067.39 in the "Zhongxiang Intelligent Manufacturing Base" project during the reporting period, with a cumulative investment of ¥45,870,787.43[49]. Operational Challenges and Risks - The management highlighted potential risks including regulatory changes that could impact operations, urging investors to remain cautious[6]. - The company faced challenges due to a complex external economic environment and a decline in effective domestic demand, impacting overall performance in the first half of 2024[16]. - The company has maintained a strong competitive edge without significant changes in its core competencies during the reporting period[31]. Corporate Governance and Shareholder Commitments - The board of directors confirmed that all members attended the meeting, ensuring comprehensive oversight of the report[6]. - The controlling shareholder and actual controller, Dai Jianwei, expressed a continuous positive outlook on the company's business prospects and plans to hold the company's stock long-term[70]. - Shareholders are committed to not reducing their holdings by more than 25% of the shares registered in their name at the end of the previous year within two years after the lock-up period expires[70]. - The company will strictly fulfill all public commitments made during the initial public offering process[71]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[78]. Legal and Compliance Matters - There are no significant lawsuits or arbitration matters reported during the reporting period[79]. - The company has not issued any guarantees during the reporting period, with a total guarantee balance of zero[83]. - The company has confirmed that it has not violated any court judgments or failed to repay significant debts during the reporting period[79]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the enterprise accounting standards, reflecting the company's financial position and operating results accurately[140]. - The company applies specific accounting policies for business combinations, distinguishing between same-control and non-same-control mergers[145]. - The company recognizes the fair value of identifiable assets and liabilities of subsidiaries acquired under non-common control mergers from the acquisition date[149].